Cooper Companies, Inc.
COONasdaqOphthalmic GoodsFiscal year ends October 31
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 16/3040% below fair value
$60.75+0.03 (+0.05%)
Close on Nov 18, 2026Market cap $11.55BP/E 20.7Yield –
Cooper Companies Interventional Clinical Studies Started by Year
Periods
Cooper Companies Interventional Clinical Studies Started: 7 in FY2026, up 16.7% from a year earlier.
Latest, FY2026
7
Period ended Oct 31, 2026 (CY2026)
Change on a year earlier
+16.7%
6 in FY2025
History
11 years
Since FY2016
Sources
1
U.S. National Library of Medicine — ClinicalTrials.gov Registry
Where the FY2026 figure comes from
Source: U.S. National Library of Medicine — ClinicalTrials.gov Registry ↗
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Cooper Companies Interventional Clinical Studies Started, annual FY2016–FY2026 [Data set]. Compiled from Cooper Companies SEC filings and investor materials. https://stockdatahq.com/stocks/coo/kpis/ct-interventional-studies
See every metric in the Cooper Companies KPI table. Data updated Nov 18, 2026.
See a number that looks wrong?